1. Home
  2. MESO vs TRS Comparison

MESO vs TRS Comparison

Compare MESO & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • TRS
  • Stock Information
  • Founded
  • MESO 2004
  • TRS 1986
  • Country
  • MESO Australia
  • TRS United States
  • Employees
  • MESO N/A
  • TRS N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • TRS Industrial Specialties
  • Sector
  • MESO Health Care
  • TRS Industrials
  • Exchange
  • MESO Nasdaq
  • TRS Nasdaq
  • Market Cap
  • MESO 1.3B
  • TRS 1.5B
  • IPO Year
  • MESO N/A
  • TRS 2007
  • Fundamental
  • Price
  • MESO $14.82
  • TRS $39.00
  • Analyst Decision
  • MESO Buy
  • TRS Strong Buy
  • Analyst Count
  • MESO 3
  • TRS 2
  • Target Price
  • MESO $18.00
  • TRS $45.00
  • AVG Volume (30 Days)
  • MESO 230.7K
  • TRS 574.3K
  • Earning Date
  • MESO 08-28-2025
  • TRS 11-03-2025
  • Dividend Yield
  • MESO N/A
  • TRS 0.41%
  • EPS Growth
  • MESO N/A
  • TRS N/A
  • EPS
  • MESO N/A
  • TRS 0.91
  • Revenue
  • MESO $17,198,000.00
  • TRS $973,840,000.00
  • Revenue This Year
  • MESO $293.59
  • TRS $11.03
  • Revenue Next Year
  • MESO $218.64
  • TRS $6.13
  • P/E Ratio
  • MESO N/A
  • TRS $42.88
  • Revenue Growth
  • MESO 191.39
  • TRS 6.72
  • 52 Week Low
  • MESO $6.00
  • TRS $19.33
  • 52 Week High
  • MESO $22.00
  • TRS $39.71
  • Technical
  • Relative Strength Index (RSI)
  • MESO 50.33
  • TRS 64.11
  • Support Level
  • MESO $12.66
  • TRS $37.85
  • Resistance Level
  • MESO $15.67
  • TRS $39.71
  • Average True Range (ATR)
  • MESO 0.45
  • TRS 0.92
  • MACD
  • MESO -0.00
  • TRS -0.21
  • Stochastic Oscillator
  • MESO 59.83
  • TRS 65.87

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products primarily for the consumer products, aerospace & defense, and industrial markets . The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.

Share on Social Networks: